SPA Pricing Education, Analytics & Decision Making Tools Webinar Series

Tag: Price Gouging

New budget test puts UK on front line in global drug price fight | Reuters

New budget test puts UK on front line in global drug price fight | Reuters

RESPONSIBLE PRICING Carole Longson, director of NICE’s center for health technology evaluation, says the onus is on drugmakers to price medicines responsibly. “Given the pace of technological innovation, the demands of people who need healthcare and the return on investments that shareholders wish for, the system is struggling,” she said. “We need to find ways […]

The good and bad of dynamic pricing | TODAYonline

The good and bad of dynamic pricing | TODAYonline

Last week, ride-hailing platform Grab announced that it would partner five taxi companies (SMRT, Premier, Trans-Cab, HDT Singapore Taxi and Prime) to introduce dynamic pricing for taxi rides booked through the app. This came after the taxi firms informed the Public Transport Council a few weeks ago of their plans to introduce fares that fluctuate […]

Dynamic pricing: Taxi data must be more transparent | TODAYonline

Dynamic pricing: Taxi data must be more transparent | TODAYonline

For commuters, dynamic taxi pricing is a mixed blessing: A greater chance of getting a taxi during rush hour but at a higher fare (Surge pricing: Taxis should also offer competitive fares; March 20). The taxi companies think this is a way to match demand with supply and to incentivise their drivers. So far, no […]

Grab to implement dynamic pricing starting from 29 March | The Online Citizen

Grab to implement dynamic pricing starting from 29 March | The Online Citizen

Ride-hailing application provider Grab has announced that it will implement dynamic pricing, JustGrab, starting from next Wednesday (29 March), following approval granted by the transport authorities last week. The new system will be put on trial starting from today among Grab employees and commuters on its rewards programme. The move means that commuters who book […]

U.S. lawmakers seek pricing info on PTC Therapuetics’ Duchenne drug | WHTC

U.S. lawmakers seek pricing info on PTC Therapuetics’ Duchenne drug | WHTC

(Reuters) – Two U.S. lawmakers sent a letter on Wednesday to PTC Therapeutics Inc, seeking information about the drugmaker’s pricing strategy for its recently acquired muscle-wasting disorder drug. PTC said last week that it would buy Marathon Pharmaceuticals LLC’s recently approved Duchenne muscular dystrophy drug (DMD), Emflaza, and promised to re-examine the hefty U.S. price […]

The Public Discourse Around Pharma and Biotech Pricing and What the Industry Can Do | Klick Health

The Public Discourse Around Pharma and Biotech Pricing and What the Industry Can Do | Klick Health

The pharma and biotech industries continue to face the perception of unfair drug pricing. If left unchecked the result will be an irreversible vilification of pharma as a whole. What can we do to mitigate these perceptions, and convey actual benefits? The views expressed here are those of the author and not necessarily those of […]

The dynamic pricing conundrum | The New Paper

The dynamic pricing conundrum | The New Paper

Four taxi companies are expected to roll out a “dynamic pricing” option later this week, a pricing mechanism used by private-hire services Uber and GrabCar. ComfortDelGro said it will hold off dynamic pricing for the moment and Prime has not given a firm indication of whether it will introduce such a system. While flat charges […]

Trump blasts Big Pharma again — “somebody’s getting very rich” — and promises drug price legislation | ENDPOINTS NEWS

Trump blasts Big Pharma again — “somebody’s getting very rich” — and promises drug price legislation | ENDPOINTS NEWS

On Mon­day Eli Lilly CEO Dave Ricks out­lined his com­pany’s case that their drug prices are not spin­ning out of con­trol. In a lengthy re­port he as­serted that dis­counts on drug prices to pharma ben­e­fit man­agers has grown from 28% in 2012 to an av­er­age of 50% last year. And while list prices grew 14% […]

Trump blasts Big Pharma again — “somebody’s getting very rich” — and promises drug price legislation | ENDPOINTS NEWS

Trump blasts Big Pharma again — “somebody’s getting very rich” — and promises drug price legislation | ENDPOINTS NEWS

On Mon­day Eli Lilly CEO Dave Ricks out­lined his com­pany’s case that their drug prices are not spin­ning out of con­trol. In a lengthy re­port he as­serted that dis­counts on drug prices to pharma ben­e­fit man­agers has grown from 28% in 2012 to an av­er­age of 50% last year. And while list prices grew 14% […]

There’s a Middle Ground in Amgen’s Drug-Price Battle | Bloomberg Gadfly

There’s a Middle Ground in Amgen’s Drug-Price Battle | Bloomberg Gadfly

The February news that Amgen Inc.’s cholesterol-lowering drug Repatha helped prevent heart attacks was one of the most exciting biotech events of the year, renewing faith in the drug’s blockbuster potential. But the full trial results behind that headline, which Amgen released on Friday, disappointed investors, sinking the company’s shares more than 6 percent. Repatha’s sales have […]